PACB vs. QTRX, FLDM, HBIO, LIFE, BLI, BNGO, TMO, A, MTD, and WAT
Should you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE), Berkeley Lights (BLI), Bionano Genomics (BNGO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), and Waters (WAT).
Quanterix (NASDAQ:QTRX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.
Quanterix has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500.
Pacific Biosciences of California received 178 more outperform votes than Quanterix when rated by MarketBeat users. Likewise, 67.32% of users gave Pacific Biosciences of California an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
86.5% of Quanterix shares are owned by institutional investors. 6.9% of Quanterix shares are owned by insiders. Comparatively, 1.9% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Quanterix has higher earnings, but lower revenue than Pacific Biosciences of California. Quanterix is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -148.13%. Pacific Biosciences of California's return on equity of -10.39% beat Quanterix's return on equity.
Quanterix presently has a consensus price target of $30.60, suggesting a potential upside of 90.89%. Pacific Biosciences of California has a consensus price target of $6.59, suggesting a potential upside of 239.74%. Given Quanterix's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than Quanterix.
In the previous week, Pacific Biosciences of California had 4 more articles in the media than Quanterix. MarketBeat recorded 7 mentions for Pacific Biosciences of California and 3 mentions for Quanterix. Pacific Biosciences of California's average media sentiment score of 1.59 beat Quanterix's score of 1.06 indicating that Quanterix is being referred to more favorably in the media.
Summary
Quanterix beats Pacific Biosciences of California on 11 of the 19 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacific Biosciences of California Competitors List
Related Companies and Tools
